Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ADMS to report 3Q20 loss of $ 0.48 per share.
For the full year, analysts anticipate top line of $ 76.67 million, while looking forward to loss of $ 1.92 per share bottom line.
Previous Quarter Performance
Adamas Pharmaceuticals, Inc. came out with loss for the second quarter of $ 0.37 per share, from the revenue of $ 18.79 million. The quarterly revenues escalated 48.07 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.61 per share from $ 15.32 million in revenue. The bottom line results beat street analysts by $ 0.24 or 39.34 percent, at the same time, top line results outshined analysts by $ 3.47 million or 22.65 percent.
Stock Performance
Shares of Adamas Pharmaceuticals, Inc. traded up $ 0.01 or 0.29 percent on Wednesday, reaching $ 3.50 with volume of 293.70 thousand shares. Adamas Pharmaceuticals, Inc. has traded high as $ 3.64 and has cracked $ 3.45 on the downward trend
The closing price of $ 3.50, representing a 83.68 % increase from the 52 week low of $ 1.90 and a 53.15 % decrease over the 52 week high of $ 7.45.
The company has a market capital of $ 98.99 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Adamas Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.adamaspharma.com
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
